🔬 The system uses industry-standard equipment, reducing human errors and lowering manufacturing costs by approximately 70%.
💡 The automation technique can be added to existing processes without the need for redesigning.
🏭 Leading companies in the biopharma equipment space, such as GenScript and Thermo Fisher, are partnering with Multiply Labs.
⚙️ The automated process improves repeatability, decreases errors, and reduces necessary production space.
✅ The goal is to automate the major processing instruments used in cell and gene therapy manufacturing.
Introduction:
Automating cell therapy manufacturing using industry-standard equipment can lead to improved efficiency, reduced errors, and lower costs. Multiply Labs has developed a vendor-agnostic robotic technique that can be added to existing manufacturing processes, eliminating the need for process redesign. By partnering with biopharma equipment leaders, Multiply Labs ensures compatibility with widely used instruments and consumables. The automation of cell and gene therapy manufacturing has the potential to transform an artisanal and costly process into a more standardized and scalable one.
- Multiply Labs has developed a robotic technique to automate cell therapy manufacturing that can be added to existing processes.
- The approach is vendor-agnostic, allowing compatibility with widely used instruments and consumables.
- The automation of cell and gene therapy manufacturing can reduce errors and improve efficiency.
- The technique has been shown to produce statistically comparable quality to manual processes, with a decrease in variation and errors.
- Multiply Labs aims to automate the leading instruments for GMP manufacturing, using a modular approach to allow for easy integration and scalability.
Conclusion:
Automating cell and gene therapy manufacturing using a vendor-agnostic robotic technique has the potential to revolutionize the field by reducing errors, improving efficiency, and lowering costs. By integrating automation with existing processes, manufacturers can benefit from standardized equipment without the need for process redesign. With continued advancements in automation technology, the future of cell and gene therapy manufacturing looks promising.
